Jan 6, 2022 7:30 am EST Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event
Nov 9, 2021 4:01 pm EST Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates
Oct 13, 2021 7:00 am EDT Avalo to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
Sep 17, 2021 9:11 am EDT Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares
Sep 14, 2021 10:23 pm EDT Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
